Format

Send to

Choose Destination
Artif Cells Nanomed Biotechnol. 2018 May;46(3):447-451. doi: 10.1080/21691401.2017.1337023. Epub 2017 Jul 4.

Lung regeneration using amniotic fluid mesenchymal stem cells.

Author information

1
a Department of Internal Medicine , Lorestan University of Medical Sciences , Khoramabad , Iran.
2
b Department of Medical Biotechnology, School of advanced Technologies in Medicine, Tehran , University of Medical sciences , Tehran , Iran.

Abstract

Respiratory diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary hypertension and lung fibrosis, are yet a major challenge in the world and they result in irreversible structural lung damage. Lung transplantation as the only therapeutic option face some major challenges like graft rejection and cancer, arising as a result of immunosuppression. A low survival rate faced by lung transplantation patients is presently limited to approximately 5 years. Lungs shortage therefore calls for a mechanism that would increase the availability of suitable organs for transplantation. In this review, we give an update on the use of amniotic fluid mesenchymal stem cells (AFMSCs) as an optimal source for lungs scaffold re-cellularization, due to their limitless accessibility and possibility for proliferation and differentiation. Further studies will be required in tissue engineering (TE) and regenerative medicine (RM), especially shifting our focus towards AFMSCs as a cell source for this regeneration.

KEYWORDS:

Re-cellularization; amniotic fluid mesenchymal stem cells; lung; regeneration

PMID:
28675062
DOI:
10.1080/21691401.2017.1337023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center